All In Biotech

Drug Trial Radar · NCT07365462

Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Feb 6, 2026

Primary completion

Feb 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Jan 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.

Conditions

  • Tardive Dyskinesia

Interventions

  • NBI-1065890Drug

    Oral administration

  • PlaceboDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 8 Based on the Blinded Central AIMS Video Raters' AssessmentTime frame: Baseline and Week 8

Locations

48 sites in 6 countries. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Bryant, Arkansas · Recruiting

  • Neurocrine Clinical Site

    Chino, California · Recruiting

  • Neurocrine Clinical Site

    Fountain Valley, California · Recruiting

  • Neurocrine Clinical Site

    Huntington Beach, California · Recruiting

  • Neurocrine Clinical Site

    Long Beach, California · Recruiting

  • Neurocrine Clinical Site

    San Diego, California · Recruiting

  • Neurocrine Clinical Site

    Temecula, California · Recruiting

  • Neurocrine Clinical Site

    Torrance, California · Recruiting

  • Neurocrine Clinical Site

    Boca Raton, Florida · Recruiting

  • Neurocrine Clinical Site

    Bonita Springs, Florida · Recruiting

  • Neurocrine Clinical Site

    Hialeah, Florida · Recruiting

  • Neurocrine Clinical Site

    Hialeah, Florida · Recruiting

  • Neurocrine Clinical Site

    Miami, Florida · Recruiting

  • Neurocrine Clinical Site

    Orange City, Florida · Recruiting

  • Neurocrine Clinical Site

    Port Charlotte, Florida · Recruiting

  • Neurocrine Clinical Site

    Tampa, Florida · Recruiting

  • Neurocrine Clinical Site

    Atlanta, Georgia · Recruiting

  • Neurocrine Clinical Site

    Marietta, Georgia · Recruiting

  • Neurocrine Clinical Site

    Naperville, Illinois · Recruiting

  • Neurocrine Clinical Site

    Ann Arbor, Michigan · Recruiting

  • Neurocrine Clinical Site

    Bloomfield Hills, Michigan · Recruiting

  • Neurocrine Clinical Site

    Saint Charles, Missouri · Recruiting

  • Neurocrine Clinical Site

    Lincoln, Nebraska · Recruiting

  • Neurocrine Clinical Site

    Commack, New York · Recruiting

  • Neurocrine Clinical Site

    Charlotte, North Carolina · Recruiting

  • Neurocrine Clinical Site

    Beachwood, Ohio · Recruiting

  • Neurocrine Clinical Site

    Fairlawn, Ohio · Recruiting

  • Neurocrine Clinical Site

    Austin, Texas · Recruiting

  • Neurocrine Clinical Site

    Fort Worth, Texas · Recruiting

  • Neurocrine Clinical Site

    Houston, Texas · Recruiting

  • Neurocrine Clinical Site

    Stafford, Texas · Recruiting

  • Neurocrine Clinical Site

    Cherven Bryag, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Kardzhali, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Novi Iskar, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Plovdiv, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Plovdiv, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Sofia, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Sofia, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Varna, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Veliko Tarnovo, Bulgaria · Recruiting

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.